May 19, 2009Risk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic Risk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic
BRisk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic Source: www.fda.gov Guidance for Industry Submission of Summary Bioequivalence Data for ANDAs Source: www.fda.gov Hydroxycut Products Dietary supplements are associated with serious liver injury, including liver failure, seizures, cardiovascular disorders, and rhabdomyolysis. Source: www.fda.gov # posted by Network @ 1:38 AM
 |
Subscribe to Posts [Atom]